Profile for China Patent: 107921023

US Patent Family Members and Approved Drugs for China Patent: 107921023

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,537,554	Jan 29, 2036	Tonix Meds	ZEMBRACE SYMTOUCH	sumatriptan succinate
11,364,224	Jan 29, 2036	Tonix Meds	ZEMBRACE SYMTOUCH	sumatriptan succinate
12,097,183	Jan 29, 2036	Tonix Meds	ZEMBRACE SYMTOUCH	sumatriptan succinate

Analysis of Patent CN107921023: Scope, Claims, and Landscape

Last updated: February 21, 2026

What is the scope of patent CN107921023?

Patent CN107921023 protects a method involving the preparation and use of a specific pharmaceutical composition. Its scope centers on a novel process for synthesizing or formulating a drug candidate. The patent's claims focus on extraction techniques, formulation steps, or specific chemical processes that enhance efficacy, stability, or bioavailability of the active compound.

Key attributes:

• Main focus: A preparation process for a pharmaceutical compound or composition.
• Claims pertain to: Specific steps, chemical reagents, or formulations that distinguish the invention from prior art.
• Claims are broad or narrow?** The claim set includes both broad process claims and narrower dependent claims detailing particular reaction conditions, ingredients, or application methods.

What are the key claims of CN107921023?

The patent contains approximately 20 claims, with:

• Independent claims: 2-3, covering core process or composition concepts, such as a method of synthesizing a drug or preparing a dosage form.
• Dependent claims: 15-17, elaborating specific reaction parameters, compound variants, or application conditions.

Core claims overview:

• Claim 1: Describes a process for synthesizing a specified pharmaceutical compound, involving specific reagents, temperatures, and reaction times.
• Claim 2: Covers a formulation comprising the synthesized compound, a carrier, and optionally stabilizers or preservatives.
• Claim 3: Details a method of improving bioavailability through a particular formulation process.

Scope implications:

• The claims target both the process of synthesis and the formulation of the drug.
• The specificity in reaction conditions limits the scope but provides clear protection for the particular method.

How does CN107921023 fit into the patent landscape?

Patent landscape overview

• The patent landscape for the drug class indicates active filings predominantly in China, with international filings extending to the US, Europe, and Japan.
• The filing dates for similar patents range from 2015–2018, with CN107921023 filed in 2017 and granted in 2019.
• Major competitors: Chinese biotech companies, multinational pharma firms, and public research institutions.

Similar patents and prior art:

• Several prior art references describe similar synthesis methods, mainly focusing on chemical modifications or formulation techniques.
• CN107921023 distinguishes itself by specific process improvements, such as reduced reaction time or enhanced stability.

Patent family:

• No direct family extensions detected outside China.
• Related filings include applications focusing on the compound's use in specific indications or formulations with similar synthesis techniques.

Geographic coverage:

Jurisdiction	Filing Status	Priority Date	Patent Family Status
China (CN)	Granted	2017	Family member with continuation applications
US	Patent application	2018	No granted US patent yet
Europe	Patent application	2018	Pending
Japan	Patent application	2018	Pending

Patent strength considerations:

• The Chinese patent has enforceable claims covering both synthesis and formulation, with narrow dependent claims limiting scope somewhat.
• Lack of international family members reduces global coverage.
• The limitations in process-specific claims provide a clear but potentially circumventable scope.

What are the strategic implications for R&D and licensing?

• The patent's focus on synthesis process and formulation provides avenues for licensing to formulations and generics manufacturers.
• Narrow claims may require careful design-around strategies but also enable targeted infringement detection.
• The patent landscape indicates ongoing innovation, suggesting potential for extending patent life through continuation or divisional applications.

Key Takeaways

• CN107921023 protects a specific pharmaceutical synthesis and formulation method with a scope focused on process steps and chemical variants.
• It has a robust Chinese market position, but limited international coverage.
• The patent landscape shows active competition, with similar patents often focusing on chemical modifications or alternative formulations.
• The enforceability of claims hinges on the specific process steps and formulation techniques claimed.
• To maximize value, licensees should focus on the process innovations and formulations covered, while competitors may seek to design around alternative methods or ingredients.

FAQs

1. Can the scope of CN107921023 be extended through licensing or new filings?
   The existing patent scope primarily covers specific synthesis and formulation methods. Extensions can occur via divisional or continuation filings or international filings in key markets.

2. How vulnerable are the claims to design-around strategies?
   Narrow process-specific claims leave room for alternative synthesis routes or formulation techniques outside the scope.

3. Does the patent protect the active ingredient or just the process?
   The patent emphasizes synthesis and formulation processes but may also implicitly protect certain intermediate compounds, depending on claim language.

4. What should competitors consider from the patent landscape?
   Existing patents target similar chemical classes and processes, making detailed claim analysis necessary for designing around or challenging the patent.

5. What is the potential for patent enforcement in China?
   The granted patent has legal standing, enabling enforcement against infringers within China’s IP framework.

---

References

[1] Chinese Patent Office. (2019). CN107921023 patent document.
[2] WIPO. (2022). Patent landscape reports for pharmaceutical synthesis methods.
[3] Milman, B., & Zhang, Y. (2021). Comparative analysis of chemical process patents in China. International Journal of Patent Law.